News release: Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel Covid-19 oral antiviral treatment candidate in reducing risk of hospitalization or death Commentaries: Pfizer’s Covid pill remains 89% effective in final analysis, company says – STAT Pfizer confirms COVID pill’s results, potency versus omicron – Associated Press Related: 8 lingering questions […]

The post [Press release – not published yet] Pfizer’s Covid pill remains 89% effective for reducing the risk of hospitalization or death in final analysis. appeared first on Links Medicus.